Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
To determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of CV death, MI, stroke or hospitalization for CHF in patients who are intolerant to ACE-I.
Parallel group design.
Cardiovascular death Non-fatal myocardial infarction Non-fatal stroke Hospitalization for congestive heart failure. Secondary endpoints: Newly diagnosed CHF. CV revascularization procedures. Newly diagnosed diabetes. Cognitive decline (adjudication done by a special committee), new onset of atrial fibrillation, nephropathy. All primary and secondary endpoints were adjudicated.